India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/laurus-labs" target="_blank" data-smartkarma-citation="entities:23686:1" rel="noopener">Laurus Labs (LAURUS IN)</a> achieved a 122% YoY increase in PAT for FY25, driven by strong CDMO execution and higher margins.</li>
<li>The company is accelerating its transformation from an ARV-heavy model to a diversified CDMO/CMO business, with growing client base and strong pipeline visibility.</li>
<li>Laurus’ focus on small molecule and bio-CDMO segments, supported by strategic investments in new capacities, positions the company for continued growth, with improved asset turnover and higher operating leverage.</li>
</ul>



Laurus Labs (LAURUS IN) achieved a 122% YoY increase in PAT for FY25, driven by strong CDMO execution and higher margins.
The company is accelerating its transformation from an ARV-heavy model to a diversified CDMO/CMO business, with growing client base and strong pipeline visibility.
Laurus’ focus on small molecule and bio-CDMO segments, supported by strategic investments in new capacities, positions the company for continued growth, with improved asset turnover and higher operating leverage.


Laurus Labs Q4 FY25 Update: Diversification and Strategic R&D Drive Growth

<ul>
<li>The company is expected to see multiple capacity expansions coming online in FY26, with ramp-up occurring throughout FY26 and FY27 onwards.</li>
<li>Currently, execution challenges and unavoidable delays have impacted the company’s revenue and margin trajectory, resulting in depressed margins on a short-term basis.</li>
<li>As new projects come online and product ramp-ups occur, it expects revenue and margin expansion, ultimately reflecting in the bottom line due to the increased gross block &amp; new products.</li>
</ul>


The company is expected to see multiple capacity expansions coming online in FY26, with ramp-up occurring throughout FY26 and FY27 onwards.
Currently, execution challenges and unavoidable delays have impacted the company’s revenue and margin trajectory, resulting in depressed margins on a short-term basis.
As new projects come online and product ramp-ups occur, it expects revenue and margin expansion, ultimately reflecting in the bottom line due to the increased gross block &amp; new products.


External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

<ul><li>Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment.</li><li>Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.</li><li>Apart from chemical synthesis-based CDMO, LAURUS is enhancing its capacities/capabilities in bio-based CDMO activities through a JV with Eight Roads (investment of INR1.6b to start with).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment.Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.Apart from chemical synthesis-based CDMO, LAURUS is enhancing its capacities/capabilities in bio-based CDMO activities through a JV with Eight Roads (investment of INR1.6b to start with).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Laurus Labs - Beat on Earnings; Green Shoots Visible

<ul><li>Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25.</li><li>It witnessed an improving traction in the CDMO business, with a 33%/44% YoY/QoQ jump in sales for 2QFY25.  However, this was offset by weak API segment.</li><li>The commercialization of CDMO contracts is expected to pick up in 2HFY25, driving sales as well as operating leverage.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25.It witnessed an improving traction in the CDMO business, with a 33%/44% YoY/QoQ jump in sales for 2QFY25.  However, this was offset by weak API segment.The commercialization of CDMO contracts is expected to pick up in 2HFY25, driving sales as well as operating leverage.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Laurus Labs - In-Line Quarter; CDMO Traction to Pick up in 2HFY25

Global Healthcare Analyst

Tina Banerjee

Equity Capital Markets

Anthem Biosciences / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/anthem-biosciences" target="_blank" data-smartkarma-citation="entities:44206:1" rel="noopener">Anthem Biosciences (1234D IN)</a>, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for INR34B IPO. The proposed IPO will be only offer for sale, with no fresh issue.</li>
<li>Anthem Biosciences is one of three CRDMOs that possess technological capabilities in India across ADCs, RNAi, peptides, and oligonucleotides, which are among the fastest growing in the pharmaceutical industry.</li>
<li>Differentiated technological capabilities, large clientele, and exposure to commercialized molecules enhance our conviction on the sustainable growth prospect of the company. Industry backdrop is also favorable.</li>
</ul>



Anthem Biosciences (1234D IN), a Contract Research, Development, and Manufacturing Organization, has filed DRHP for INR34B IPO. The proposed IPO will be only offer for sale, with no fresh issue.
Anthem Biosciences is one of three CRDMOs that possess technological capabilities in India across ADCs, RNAi, peptides, and oligonucleotides, which are among the fastest growing in the pharmaceutical industry.
Differentiated technological capabilities, large clientele, and exposure to commercialized molecules enhance our conviction on the sustainable growth prospect of the company. Industry backdrop is also favorable.


Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

India

Laurus Labs Limited researches, develops, manufactures, and sells active pharmaceutical ingredients (APIs) in India and internationally. It offers APIs for anti-retroviral and hepatitis C; and APIs in oncology and other therapeutic areas. .

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laurus Labs (LAURUS IN)

Laurus Labs Q4 FY25 Update: Diversification and Strategic R&D Drive Growth

Laurus Labs sees 122% YoY increase in PAT for FY25, driven by CDMO success and margin growth, transforming into diversified CDMO/CMO business with...

Sudarshan Bhandari

The Beat Ideas: Laurus Labs

Company faces short-term challenges with revenue and margins due to delays, but expects expansion and improved bottom line in FY26 and beyond with...

Sudarshan Bhandari

Laurus Labs - Beat on Earnings; Green Shoots Visible

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment.Commercial supplies (including...

Motilal Oswal

Laurus Labs - In-Line Quarter; CDMO Traction to Pick up in 2HFY25

Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25. It witnessed an improving traction in the CDMO business, with a...

Motilal Oswal

Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for an Indian IPO. The proposed IPO will be...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Laurus Labs Q4 FY25 Update: Diversification and Strategic R&D Drive Growth

​Laurus Labs sees 122% YoY increase in PAT for FY25, driven by CDMO success and margin growth, transforming into diversified CDMO/CMO business with...

Sudarshan Bhandari

The Beat Ideas: Laurus Labs

​Company faces short-term challenges with revenue and margins due to delays, but expects expansion and improved bottom line in FY26 and beyond with...

Sudarshan Bhandari

Laurus Labs - Beat on Earnings; Green Shoots Visible

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment.Commercial supplies (including...

Motilal Oswal

Laurus Labs - In-Line Quarter; CDMO Traction to Pick up in 2HFY25

Laurus Lab (LAURUS) delivered largely in-line operational performance for 2QFY25. It witnessed an improving traction in the CDMO business, with a...

Motilal Oswal

Anthem Biosciences Pre-IPO: High Visibility Powered by Differentiated Capabilities

Anthem Biosciences, a Contract Research, Development, and Manufacturing Organization, has filed DRHP for an Indian IPO. The proposed IPO will be...

Tina Banerjee

Laurus Labs sees 122% YoY increase in PAT for FY25, driven by CDMO success and margin growth, transforming into diversified CDMO/CMO business with...

Company faces short-term challenges with revenue and margins due to delays, but expects expansion and improved bottom line in FY26 and beyond with...